95 exclusive proprietary Chinese medicines are on display!

With the acceleration of the centralized procurement of Chinese patent medicines and the release of the dividends of the Chinese medicine policy, retail pharmacies are expected to become a new battlefield for Chinese patent medicines
.
According to data from Minet.
com, it is estimated that in 2021, the market size of Chinese urban physical pharmacies and Chinese online pharmacy terminals will be close to 120 billion yuan
.
In 2021E, the terminal sales of 95 exclusive Chinese patent medicines in physical pharmacies in Chinese cities exceeded 100 million yuan, with a total market size of more than 20 billion yuan, of which 14 had a sales growth rate of more than 20%.
Yiling, Yunnan Baiyao, Guangyao, China Resources, Tasly, Eight pharmaceutical companies including Yangzijiang dominate the screen
.
The process of centralized procurement of proprietary Chinese medicines has accelerated, and retail pharmacies may become a new battlefield.
Since last year, the pace of centralized procurement of proprietary Chinese medicines has continued to accelerate
.
The centralized procurement of Chinese patent medicines in the 19-province alliance in Hubei will officially "end" at the end of 2021, and it has now entered the stage of distributing the procurement volume
.
The centralized procurement involved 76 major varieties, with a procurement scale of nearly 10 billion yuan.
In the end, 97 companies and 111 products were selected, with a selection rate of 62%, an average drop of 42.
27%, and a maximum drop of 82.
63%
.
In addition, the centralized procurement of Chinese patent medicines of the 6-province alliance in Guangdong also announced the results of the proposed selection/alternative recently.
The centralized procurement involved 53 major varieties.
In the end, 361 products from 174 companies were proposed to be selected/alternative.
Among them, the exclusive varieties proposed to win the bid on average.
The decline is around 20%, and the average decline in bids for non-exclusive varieties is 67.
8%
.
As the centralized procurement of Hubei Alliance and Guangdong Alliance covering most of China has settled, the special centralized procurement of proprietary Chinese medicines has officially entered the substantive start-up stage from the level of discussion and preparation
.
The centralized procurement of the two major Chinese patent medicine alliances will provide an important reference for the subsequent possible national procurement of Chinese patent medicines and other inter-provincial alliances
.
Centralized procurement not only tests the production capacity of pharmaceutical companies, but also tests their cost control ability and price reduction flexibility.
The market faces more uncertainty, and retail pharmacies are expected to be the new battleground
.
According to data from Minet.
com, it is estimated that the sales volume of Chinese patent medicines in urban physical pharmacies and online pharmacies in China will be close to 120 billion yuan in 2021, a year-on-year increase of 5.
2%.
Among them, physical pharmacies are still the "main battlefield" for the sales of Chinese patent medicines, and the market size is expected to decrease slightly in 2021.
In 2021, sales of online pharmacies will exceed 10 billion yuan, a year-on-year increase of more than 50%
.
In recent years, sales of Chinese patent medicines in physical pharmacies in Chinese cities and online pharmacies in China (unit: 100 million yuan) Source: Minet Database Over 20 billion market! 95 exclusive Chinese patent medicines sold over 100 million yuan According to Mi Intranet data, it is estimated that nearly 200 Chinese patent medicines will have sales of more than 100 million yuan in physical pharmacies in Chinese cities in 2021E, with a total sales scale of more than 60 billion yuan, a year-on-year increase of about 1.
9%
.
95 of the nearly 200 over 100 million Chinese patent medicines are exclusive varieties (including exclusive dosage forms), with a total sales scale of more than 20 billion yuan
.
In 2021E, the source of exclusive Chinese patent medicines with sales of over 100 million in Chinese urban physical pharmacies: Minet.
com The competitive landscape of Chinese urban physical pharmacies 95 exclusive Chinese patent medicines cover 13 major categories of treatment, focusing on drugs for respiratory diseases (20), cardiovascular and cerebrovascular diseases Drugs for diseases (13) and drugs for digestive system diseases (12), it can be seen that Chinese patent medicines for common diseases and chronic diseases are more popular in physical pharmacies
.
National medical insurance and OTC products are the mainstream
.
Among the 95 exclusive Chinese patent medicines, 63 are included in the 2021 National Medical Insurance Catalogue (28 Class A, 35 Class B), and 63 are OTC products (32 double-cross products)
.
In terms of sales, Shujin Jianyao Pills (Guangzhou Baiyunshan Chenliji Pharmaceutical Factory), Kyoto Nianci'an Honey Lianchuanbei Loquat Cream (Kyoto Nianci'an General Factory), and Lianhua Qingwen Capsules (Shijiazhuang Yiling Pharmaceutical) are three major varieties.
Over 1 billion, of which Shujin Jianyao Pill will replace Lianhua Qingwen Capsule as the best-selling exclusive Chinese patent medicine in 2021E Chinese urban physical pharmacy terminals
.
In addition, the three varieties of Changyanning Tablets (Jiangxi Kangenbei Traditional Chinese Medicine), Pien Tze Huang (Zhangzhou Pien Tze Huang Pharmaceutical), and Lanqin Oral Liquid (Yangtze River Pharmaceutical) are approaching the 1 billion mark
.
14 varieties soared by more than 20%, Tasly, Yangzijiang .
.
.
8 companies are outstanding From the growth rate, 59 of the 95 exclusive Chinese patent medicines have a year-on-year increase in sales, of which 14 have an increase of more than 20%
.
2021E China's urban physical pharmacy terminal sales of over 100 million yuan and the growth rate of over 20% of the exclusive source of proprietary Chinese medicine: Minet China's urban physical pharmacy terminal competition pattern Tiepi Fengdou Granules (Zhejiang Emperor Pharmaceutical), Compound Goldenrod Spray (Guizhou Bailing Enterprise) Group Pharmaceutical), Kuntai Capsule (Guiyang Xintian Pharmaceutical), Huaier Granule (Qidong Gaitianli Pharmaceutical), New Compound Aloe Capsule (Hebei Wanbang Fulin Pharmaceutical), Xuezhikang Capsule (Beijing Peking University Weixin Biology) , Longmu Zhuanggu Granules (Jianmin Pharmaceutical Group) 7 exclusive Chinese patent medicines in the past three years have achieved double-digit and above sales growth
.
The Tiepi Fengdou Granules of Zhejiang Emperor Pharmaceutical has the effects of nourishing qi, nourishing yin, nourishing stomach and invigorating body fluid.
Tiepi Fengdou Granules ranks second with a market share of about 8% in the ranking of Chinese patent medicine products for cough, phlegm and asthma in Chinese urban physical pharmacies
.
In addition, the product's performance in China's online pharmacy terminals is also very bright, with a sales growth rate of nearly 180% in 2021
.
In recent years, sales of Tiepi Fengdou Granules in Chinese urban physical pharmacy terminals (unit: ten thousand yuan) Source: Minet Double-cross) varieties, which have the effect of strengthening tendons and bones, and strengthening the stomach and spleen, and are suitable for the treatment and prevention of rickets and osteomalacia in children
.
In the ranking of pediatric Chinese patent medicine products in Chinese urban physical pharmacy terminals, Longmu Zhuanggu Granules ranked first in 2020 for the first time, and ranked first in 2021.
A year-on-year increase of 98.
3%
.
In recent years, sales of Longmu Zhuanggu Granules in Chinese urban physical drugstore terminals (unit: ten thousand yuan) Source: Minet.
com China's urban physical drugstore terminal competition pattern 100 million exclusive Chinese patent medicines, of which 8 have 4 or more.
Yiling Pharmaceutical, Yunnan Baiyao, Beijing Tongrentang, Guangzhou Pharmaceutical Group, China Resources Pharmaceutical, Tasly, and Yangzijiang Pharmaceuticals all rank among the 2021E Chinese urban physical pharmacy terminal Chinese patent medicine manufacturers TOP20
.
Sources of 4 or more companies with over 100 million exclusive proprietary Chinese medicines: Minet.
com China's urban brick-and-mortar pharmacy terminal competition pattern Yiling Pharmaceutical's Lianhua Qingwen series products (capsules, granules, tablets), Yunnan Baiyao's Yunnan Baiyao series products ( Aerosols, patches, powders, capsules, solutions) in 2021E China's urban physical pharmacy terminals total sales of 1.
19 billion yuan and 1.
67 billion yuan respectively; in the ranking of Chinese patent medicine products in the skeletal muscle system, GPHL's Shu Jinjianyao Pill has been ranked first for many years, while Lanqin Oral Liquid of Yangzijiang has won the top sales of Chinese patent medicines in ENT for many consecutive years
.
Source: Minet database Note: Minet China's urban physical pharmacy terminal competition pattern database is an enlarged version of urban physical pharmacies covering 297 cities and above cities across the country (excluding county and rural physical pharmacies), and continuously monitoring all categories of urban physical pharmacies Database, the above sales are calculated based on the average retail price of the product in the terminal
.
The competition pattern of China's online pharmacy terminals in Minet is an enlarged version of the online pharmacy sales database that covers all online pharmacies across the country and continuously monitors all categories
.